Pulmonary hypertension refers to a medical condition in which there is an elevated blood pressure in the pulmonary artery which can restrict blood flow to the lungs and cause the heart's right ventricle to overwork itself, leading to a variety of symptoms (including dizziness, fainting, and shortness of breath) as well a marked decreased ability to exert oneself (such as through exercise or a lot of activity).
The term primary pulmonary hypertension (PPH), although it's now being used less in the medical realm in favor of the term idiopathic pulmonary arterial hypertension, is still a term used readily in literature as well as in the general public, and refers to pulmonary hypertension that has an unknown or unverified cause.
PPH has many possible causes, but because the term primary pulmonary hypertension was coined due to the fact that its cause is unknown, specific causes are difficult to pinpoint. Causes of the different types of pulmonary hypertension in general can include left heart failure, congenital heart disease, lung diseases, HIV and other autoimmune disorders, pulmonary embolism, and genetics.
One of the biggest suspected causes of primary pulmonary hypertension is the use of certain anti-obesity and weight-loss pills, such as Fen-Phen, which the FDA took off the market in September 1997 after reports linked it to pulmonary hypertension and other conditions.
If you have primary pulmonary hypertension, you'll want to consider an effective PPH treatment. One of the most popular and beneficial PPH treatments is an FDA-approved drug called Tracleer. Why is this treatment so beneficial? Tracleer treatment, produced by Patheon Inc. and marketed by Actelion Pharmaceuticals, is a vasodilator drug in tablet form that is taken orally in order to help block the effects of endothelin, a vasoconstrictor naturally found in the body to shrink blood vessels, but is found in much higher concentrations in patients with primary pulmonary hypertension.
In addition, PPH treatment using this helps to relax the lung's blood vessels as well as increase the level of oxygen in the blood. For patients with primary pulmonary hypertension, what this means in a practical sense is that they are able to perform regular activities at an improved level, without becoming fatigued, dizzy, or short of breath right away, and they are able to tolerate exercise more.
However, like all drugs, including others used for PPH treatment, it does have a number of side-effects that patients taking it or considering its use should become aware of. Some of the more common side-effects associated with this treatment include headaches, nasal congestion, flushing out, passing out, and even abnormally low blood pressure.
The most serious possible side-effect associated with this treatment, however, involves the liver. Tracleer can actually impair normal liver function, and even cause liver damage, which may or may not be permanent in nature. As a result, patients with primary pulmonary hypertension on this treatment require monthly blood tests of the liver's function.
In addition to side-effects, Tracleer treatment also has one major contraindication: pregnant women or women who may be or are trying to become pregnant must not take it, as this particularly form of PPH treatment has been proven to be teratogenic (known to harm a fetus, cause birth defects, or miscarriage).
Therefore, in addition to monthly liver blood tests, female patients on it must take monthly pregnancy tests in case pregnancy occurs, at which point it must be stopped immediately. Further, if you're a female on Tracleer treatment and you're using a hormonal method of birth control, you will also have to supplement with a barrier method (like condoms) because it has been shown to reduce the effectiveness of birth control pills, patches, rings, injections, and implants.
While this treatment often has more side-effects and potential complications than other types of PPH treatment, such as Flolan and Remodulin (two of the other most common types of PPH treatment), it is the preferred type for many because of its convenience in that it can be taken orally.
Patients with primary pulmonary hypertension may wish to talk to their doctors about different types of PPH treatment, including Tracleer treatment. It is available by prescription only and should only be taken under a doctor's advice and directions.
If you have pulmonary hypertension with an unknown cause, and you believe you may have developed primary pulmonary hypertension because of your use of the anti-obesity, weight-loss pill Fen-Phen, then in addition to asking your doctor about Tracleer treatment, it is recommended you seek the legal counsel from a reputable law firm or PPH attorney specializing in Fen-Phen litigation cases. You may qualify for compensation.
Chronic Thromboembolic Pulmonary Hypertension
Ronald J. Oudiz, M.D., Director of Pulmonary Hypertension, Associate Professor, Department of Medicine, Division of Cardiology, Harbor-UCLA Medical Center indicated (emedicine) that:
PPH (Primary Pulmonary Hypertension), more recently termed IPAH (Idiopathic Pulmonary Arterial Hypertension) has been associated with anorexigens and other alpha-adrenergic stimulants (fen-phen). How these associated conditions predispose to, or cause, PPH remains unknown.
In the US, IPAH (PPH) is responsible for approximately 125-150 deaths per year.
Typically, younger women of childbearing age develop IPAH (PPH). However, it can also affect women in their fifth and sixth decades of life or older.
The mortality rate for untreated IPAH (PPH) is approximately 50% at 3 years (varies with severity at presentation).
The American Heart Association indicates that an estimated 500 to 1,000 new cases of PPH are diagnosed each year in the United States. The greatest number is reported in women between the ages of 20 and 40. However, men and women in all ages and very young children develop PPH.
Appetite suppressants (fen-phen) are one of the factors believed to trigger the constriction, or narrowing, of the pulmonary artery.
One website devoted to information about Primary Pulmonary Hypertension states that PPH or Pulmonary Arterial Hypertension may be linked to the diet drug fen-phen:
A significant association exists between the use of the fen-phen diet drug and PPH. Studies have shown that it can be several years (ten or more) after having stopped taking diet drugs that patients develop the disease.
The American Lung Association reports that, in 2000, there were 3,065 deaths attributed to PPH. This organization also states: The use of certain appetite suppressants (fen-phen) has been found to increase the risk of developing PPH, especially use lasting more than three months.
They report that studies estimate that treatment with certain appetite suppressant drugs (fen-phen) increases the risk of getting PPH from approximately 1, to 28 cases per million person-years (one person-year represents a patient treated for one year). Two drugs associated with PPH, fenfluramine (one of the components of fen-phen) and dexfenfluramine, were taken off the market in September 1997 after being linked to heart valve damage.
The National Heart Lung and Blood Institute identifies factors that appear to increase the chances of developing PAH (pulmonary arterial hypertension. They include the use of appetite suppressants, especially fenfluramine (fen-phen) and dexfenfluramine.
Nick Johnson has sinced written about articles on various topics from Obesity, Health and Class Action. Nick Johnson is lead counsel with Johnson Law Group. Johnson represents plaintiffs in many states and focuses on injury cases involving Fen-Phen and PPH, Paxil, Mesothelioma and Nursing Home Abuse. Call 1-888-311-5522 today or visit. Nick Johnson's top article generates over 27100 views. to your Favourites.
Cassidy Expect The Unexpected Lyrics Like all surgical procedure, it takes time to heal. For the best long-term results, you must accept that and get on with your life in the meantime